Biohaven Ltd. (BHVN)
15.69
-0.17
(-1.07%)
USD |
NYSE |
Sep 04, 16:00
15.69
0.00 (0.00%)
Pre-Market: 20:00
Biohaven Shareholders Equity (Quarterly) : 12.22M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.22M |
| March 31, 2026 | 129.50M |
| December 31, 2025 | 52.07M |
| September 30, 2025 | -17.16M |
| June 30, 2025 | 134.59M |
| March 31, 2025 | 259.50M |
| December 31, 2024 | 423.44M |
| September 30, 2024 | 316.01M |
| June 30, 2024 | 383.74M |
| Date | Value |
|---|---|
| March 31, 2024 | 301.45M |
| December 31, 2023 | 427.98M |
| September 30, 2023 | 290.01M |
| June 30, 2023 | 387.26M |
| March 31, 2023 | 472.26M |
| December 31, 2022 | 538.77M |
| September 30, 2022 | 100.22M |
| June 30, 2022 | 25.00M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| NovelStem International Corp. | -2.032M |
| Brainstorm Cell Therapeutics, Inc. | -11.60M |
| Summit Therapeutics, Inc. | 629.98M |
| Kezar Life Sciences, Inc. | 65.24M |
| Protara Therapeutics, Inc. | 161.31M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 370.74M |
| Total Liabilities (Quarterly) | 358.52M |
| Debt to Equity Ratio | 24.30 |
| Current Ratio | 4.733 |
| Net Debt Paydown Yield | -2.33% |